SCHEMBL6190856

SCHEMBL6190856

c1ccc(Nc2ccccc2-c2nnco2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 7/20 0.54
KMT2A Q03164 4/20 0.46
TSHR P16473 2/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
TLR8 Q9NR97 1/20 0.42
KDM4E B2RXH2 3/20 0.41
MEN1 O00255 2/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 2/20 0.41
GLA P06280 1/20 0.41
RECQL P46063 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
LMNA P02545 2/20 0.40
RXFP1 Q9HBX9 1/20 0.40
PDK2 Q15119 1/20 0.40
ALDH1A1 P00352 1/20 0.40
CYP1A2 P05177 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29888460 0.84 NOTUM (0.56) NOTUMKMT2ARAB9AMEN1TDP1
SCHEMBL22556460 0.84 NOTUM (0.56) NOTUMKMT2ARAB9AMEN1TDP1
SCHEMBL13363917 0.74 MAPT (0.61) KMT2ATSHRNPC1TP53RAB9A
SCHEMBL11499568 0.74 NOTUM (0.49) NOTUMKMT2ATSHRNPC1TP53
SCHEMBL4276979 0.74 NOTUM (0.70) NOTUMKMT2ATSHRNPC1TP53
SCHEMBL9265268 0.73 CLCN2 (0.57) NOTUMKMT2ATSHRMEN1GAA
SCHEMBL29871430 0.72 MAPT (0.58) KMT2ATSHRNPC1TP53RAB9A
SCHEMBL21801559 0.72 GSK3B (0.47) NOTUMKMT2ATSHRNPC1TP53
SCHEMBL29257205 0.71 MAPT (0.56) KMT2ATSHRNPC1TP53RAB9A
Fenadiazole SCHEMBL555484 0.71 NOTUM (0.61) NOTUMKMT2ATSHRNPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578736-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL-PHENYLAMINE DERIVATIVES Warner-Lambert Company LLC (US) 2005-09-28 EP disclosed
US-20050004186-A1 MEK inhibiting compounds PFIZER INC 2005-01-06 US disclosed
WO-2004056789-A1 MEK INHIBITING OXA- AND THIA-DIAZOL-2-YL PHENYLAMINE DERIVATES WARNER-LAMBERT COMPANY LLC (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004186-A1 MEK inhibiting compounds MAPK1, MAP3K1, MAPK3 NOTUM 3478/4885KMT2A 1359/4885TSHR 2576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.